The NSD1 (Nuclear Receptor Binding SET Domain Protein 1) antibody is a key tool for studying the NSD1 protein, a histone methyltransferase involved in epigenetic regulation. NSD1 catalyzes the dimethylation and trimethylation of histone H3 at lysine 36 (H3K36me2/me3), modifications linked to transcriptional activation, chromatin stability, and DNA repair. It plays critical roles in development, cellular differentiation, and oncogenesis. Dysregulation of NSD1 is associated with genetic disorders and cancers. For example, germline NSD1 mutations cause Sotos syndrome, a congenital overgrowth disorder, while somatic mutations or aberrant expression are observed in acute myeloid leukemia (AML), neuroblastoma, and other malignancies. The NSD1 antibody enables researchers to detect NSD1 expression levels, subcellular localization, and interaction partners in experimental models (e.g., Western blot, immunohistochemistry, ChIP-seq). It also aids in exploring NSD1’s context-dependent roles—either as an oncogene or tumor suppressor—depending on cellular conditions and mutation profiles. Commercial NSD1 antibodies are typically validated for specificity and application compatibility, though performance may vary across isoforms or post-translational states. Studies utilizing this antibody contribute to understanding epigenetic mechanisms in development and disease, with potential implications for targeted therapies in NSD1-driven disorders.